Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Amy Barber, PhD, John R Jones, MD, Harvey Che, Yann-Vai Le Bihan, Niels Weinhold, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Hannah Wang, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Faith E. Davies, Rajesh Chopra, MD, Gareth Morgan, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140024

Published: 2020

Journal Articles

Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138787

Published: 2020

Journal Articles

Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients

Kylee H Maclachlan, MBChB, PhD, Binbin Zheng-Lin, MDMSc, Venkata Yellapantula, PhD, Andriy Derkach, PhD, Even H Rustad, MD PhD, Benjamin Diamond, MD, Malin Hultcrantz, MD PhD, Ahmet Dogan, MD PhD, Yanming Zhang, MD, Gareth Morgan, MD PhD, Ola Landgren, MD PhD, Francesco Maura, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-137281

Published: 2020

Journal Articles

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Tom Menzies, Faith E. Davies, Ritika Rana, Jennifer Pinney, Gordon Cook, MD, Walter Martin Gregory, PhD, Matthew W Jenner, John R Jones, MD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Gareth Morgan, MD PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, David Cairns, MSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-139238

Published: 2020

Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-133516

Published: 2020

Journal Articles

The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data

Kylee H Maclachlan, MBChB, PhD, Binbin Zheng-Lin, MDMSc, Venkata Yellapantula, PhD, Even H Rustad, MD PhD, Benjamin Diamond, MD, Malin Hultcrantz, MD PhD, Ahmet Dogan, MD PhD, Yanming Zhang, MD, Gareth Morgan, MD PhD, Ola Landgren, MD PhD, Francesco Maura, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-139879

Published: 2020

Journal Articles

Analysis of Intestinal Microbiome in Multiple Myeloma Reveals Progressive Dysbiosis Compared to MGUS and Healthy Individuals

Crystal Antoine Pepeljugoski, MD, Gareth Morgan, MD PhD, Marc Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 3076.

https://doi.org/10.1182/blood-2019-130643

Published: 2019

Journal Articles

The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset

Louis Williams, MD MBA, Eileen M Boyle, MD MSc, Faith E. Davies, MD, Brian A Walker, PhD, Cody Ashby, PhD, Michael A Bauer, PhD, Christopher P. Wardell, PhD MSc, BSc, Erin Flynt, Anjan Thakurta, Gareth Morgan, MD PhD

Blood (2019) 134 (Supplement_1): 4346.

https://doi.org/10.1182/blood-2019-130079

Published: 2019

Journal Articles

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Cody Ashby, PhD, Eileen M Boyle, MD MSc, Brian A Walker, PhD, Michael A Bauer, PhD, Katie Rose Ryan, PhD, Judith Dent, Anjan Thakurta, Erin Flynt, Faith E. Davies, MD, Gareth Morgan, MD PhD

Blood (2019) 134 (Supplement_1): 3767.

https://doi.org/10.1182/blood-2019-130335

Published: 2019

Journal Articles

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Brian A Walker, PhD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4383.

https://doi.org/10.1182/blood-2019-130493

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML.

Richard Walgren, MD, PhD, Edward McLaughlin, BSc, Elise Peterson, BS, Michael Crosswhite, MA, Michael Province, PhD, Howard McLeod, PharmD, Timothy Ley, MD, Timothy Graubert, MD, Gareth Morgan, MD, PhD

Blood (2007) 110 (11): 15.

https://doi.org/10.1182/blood.V110.11.15.15

Published: 2007

NARROW

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma

Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data

Analysis of Intestinal Microbiome in Multiple Myeloma Reveals Progressive Dysbiosis Compared to MGUS and Healthy Individuals

The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only